ARA-290 (cibinetide) is best known online as an "anti-inflammatory" peptide, but its strongest published evidence is narrower and more specific: in Phase 2 trials it regrew small nerve fibers and reduced neuropathic pain in sarcoidosis patients. The general anti-inflammatory framing is real mechanistically — but the human outcome data clusters around nerve repair.
Research-context information only. ARA-290 (cibinetide) is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
ARA-290 is an 11-amino-acid peptide derived from the helix-B region of erythropoietin. It activates the innate repair receptor — a heterocomplex of the EPO receptor and the beta-common receptor (CD131) — to trigger tissue-protective signaling. The benefits below are ranked by the strength of the human evidence behind each.
Key Benefits at a Glance
Benefit
Evidence level
Source
Small nerve fiber regrowth
Human Phase 2 (primary endpoint met)
Culver 2017
Neuropathic pain reduction
Human Phase 2 (secondary outcomes)
Dahan 2013, Culver 2017
Metabolic markers in diabetes
Human Phase 2 (exploratory)
Brines 2015
Anti-inflammatory signaling
Mechanistic / preclinical
Dahan 2016 review
No effect on red blood cells
Human trials (safety)
Across trials
Small Nerve Fiber Regrowth — the strongest evidence
A 2017 dose-ranging trial reported that cibinetide met its primary endpoint for small-nerve-fiber repair: the 4 mg dose produced a significant placebo-corrected increase in corneal nerve fiber area, measured by corneal confocal microscopy, alongside a significant increase in skin intraepidermal regenerating (GAP-43-positive) nerve fibers (Culver et al., 2017). This is the most rigorous ARA-290 result — a pre-specified objective endpoint, met in a placebo-controlled trial.
An earlier 2013 trial similarly reported a significant increase in corneal small nerve fiber density after 28 days of daily ARA 290 in sarcoidosis patients (Dahan et al., 2013).
The 2013 sarcoidosis trial reported that 28 days of ARA 290 improved neuropathic symptoms and raised thresholds for painful thermal stimuli, with improvement sustained through 16 weeks of follow-up (Dahan et al., 2013). In the later dose-ranging study, subjects with moderate-to-severe baseline pain reported clinically meaningful, placebo-corrected pain reductions — strongest in the 4 mg group, though the pain endpoint did not reach statistical significance across the full sample (Culver et al., 2017). The pain signal is real but more modest than the objective nerve-fiber data.
Metabolic Markers in Type 2 Diabetes
A 2015 placebo-controlled trial administered 4 mg/day ARA 290 for 28 days in type 2 diabetes patients and reported reductions in HbA1c and improvements in lipid markers that persisted through a 56-day observation period, along with reduced neuropathic symptom scores (Brines et al., 2015). Corneal nerve fiber density increased in subjects whose baseline was reduced relative to healthy controls. These are exploratory findings from a single trial — promising, but not the focus of ARA-290's development program.
The "anti-inflammatory peptide" framing comes from mechanism, not from a dedicated inflammation endpoint. A 2016 review describes how the innate repair receptor is upregulated in injured tissue and modulates the neurogenic inflammatory response, with ARA-290 dampening spinal microglial activation in models of neuropathy (Dahan et al., 2016). The human trials measured nerve and metabolic outcomes rather than inflammatory markers directly, so the anti-inflammatory benefit is best read as the documented mechanism behind the nerve-repair results — not a separately validated clinical claim.
No Effect on Red Blood Cells
ARA-290 was deliberately engineered to separate erythropoietin's tissue-protective signaling from its erythropoietic and thrombotic effects. Across the published trials, investigators reported no significant change in hematocrit and an excellent safety profile — the design feature that distinguishes ARA-290 from EPO itself (Brines et al., 2015).
Who Is ARA-290 Studied In?
Common research audience: sarcoidosis patients with painful small-fiber neuropathy — the indication for which ARA-290 holds FDA Orphan Drug and Fast Track designations.
Secondary research audience: type 2 diabetes patients with neuropathic symptoms, studied in a single Phase 2 trial.
These describe the populations enrolled in published trials, not a recommendation for any individual.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
What did trials report about ARA-290 and neuropathic pain?
A 2013 Molecular Medicine trial (Dahan et al.) reported reduced neuropathic symptoms after 28 days of daily ARA 290 in sarcoidosis patients, sustained through 16 weeks of follow-up. A 2017 dose-ranging study (Culver et al.) reported clinically meaningful pain reductions in subjects with moderate-to-severe baseline pain, strongest at the 4 mg dose.
What did trials report about ARA-290 and nerve fiber regrowth?
Phase 2 trials reported increased corneal small nerve fiber density and increased skin intraepidermal regenerating nerve fibers after 28-day courses, measured by corneal confocal microscopy and skin biopsy.
What did trials report about ARA-290 in type 2 diabetes?
A 2015 Molecular Medicine trial (Brines et al.) reported that 4 mg/day ARA 290 for 28 days improved HbA1c and lipid markers and reduced neuropathic symptom scores, with corneal nerve fiber density increasing in subjects whose baseline was reduced.
Does ARA-290 raise red blood cell count?
No. ARA-290 was engineered to separate erythropoietin's tissue-protective signaling from its red-blood-cell-stimulating and clotting effects. Published trials reported no significant change in hematocrit.
Research Supplies for ARA-290
Hand-picked storage, injection, and recovery supplies paired with ARA-290 protocols.
This article is for educational and informational purposes only. It is not medical advice. ARA-290 is not FDA-approved for any indication. Consult a licensed healthcare provider before using any peptide.
